Seeking Alpha
 

Sequenom, Inc. (SQNM)

- NASDAQ
  • Jul. 24, 2013, 4:12 PM
    Sequenom (SQNM): Q2 EPS of -$0.27 misses by $0.06. Revenue of $34.9M misses by $11.35M. (PR)
    | Comment!
  • Jun. 12, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: SWY +30%. SPRD +25%. PVH +7%. PSMI +6%. SVU +6%.
    After-hours top losers: SIGM -8%. QCOR -7%. SQNM -5%. ECYT -3%. VLCCF -3%.
    | 3 Comments
  • Jun. 7, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: EQIS +6%. GFA +5%. VWO +4%. DLR +3%. HILL +2%.
    After-hours top losers: MIND -16%. UAL -7%. SQNM -4%. PBI -3%. ADBE -3%.
    | Comment!
  • May. 31, 2013, 11:38 AM
    Jefferies assumes Sequenom (SQNM +0.7%) at Buy (price target $6) citing momentum for the company's MaterniT21 test which analyst Brandon Couillard says is "ramp[ing] at a blistering clip." (Related: Credit Suisse sees robust test volumes)
    | Comment!
  • May. 30, 2013, 4:14 PM
    Sequenom (SQNM +1.7%) finishes higher after saying it's entered into a technology licensing and marketing agreement with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. Under the agreement, SQNM will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France, as well as Belgium, Luxembourg and portions of the Middle East and Africa. The contract is effective immediately and active through 2018.
    | Comment!
  • May. 13, 2013, 11:53 AM
    Credit Suisse upgrades Sequenom (SQNM +7.5%) to Neutral and raises its price target to $4.50 from $4, citing decreased risk stemming from the company's five-year agreement with Blue Cross and Blue Shield (see CC) for the MaterniT21 PLUS test. Analyst Vamil Divan notes that "following daily moves in [the stock] can get one dizzy" — today is no exception — but CS sees SQNM running 175K tests in FY13 versus company projections of 150K and says that ultimately, robust volumes are enough to support the story at least for the foreseeable future. (See also: Q1 earnings)
    | Comment!
  • May. 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | Comment!
  • May. 10, 2013, 9:10 AM
    Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
    Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%.
    | Comment!
  • May. 9, 2013, 5:51 PM
    More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue estimates. Total sales jumped 158% over the prior year, led by continued growth in diagnostic sales. Total cost of revenues increased, primarily due to the significant increase in its test volumes and costs to support increased testing capacity. Shares +5% AH.
    | Comment!
  • May. 9, 2013, 4:14 PM
    Sequenom (SQNM): Q1 EPS loss of -$0.26 misses by $0.02. Revenue of $38.5M (+158% Y/Y) in line. (PR).
    | Comment!
  • May. 9, 2013, 12:10 AM
    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX
    | Comment!
  • May. 8, 2013, 5:35 PM
    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX
    | Comment!
  • Apr. 4, 2013, 8:39 AM
    Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about proposed regulation of prenatal screening tests likely overstates the case as the FDA "has missed its window to regulate the non-invasive prenatal testing market." Analyst Zarak Khurshid upgrades the stock to Outperform from Neutral and reiterates a price target of $5. Shares +3.4% premarket. 
    | Comment!
  • Mar. 7, 2013, 4:16 PM
    Sequenom (SQNM): Q4 EPS of -$0.29 misses by $0.07. Revenue of $33.7M (+117% Y/Y) beats by $1.68M. Shares -2% AH. (PR)
    | Comment!
  • Mar. 7, 2013, 12:10 AM
    Notable earnings after Thursday’s close: AMBA, BPZ, FNSR, HRB, MED, P, SKUL, SQNM, WDAY, WPRT, ZQK
    | Comment!
  • Mar. 6, 2013, 5:35 PM
    Notable earnings after Thursday’s close: AMBA, BPZ, FNSR, HRB, MED, P, SKUL, SQNM, WDAY, WPRT, ZQK
    | Comment!
Visit Seeking Alpha's
SQNM vs. ETF Alternatives
Company Description
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.
Sector: Healthcare
Industry: Biotechnology
Country: United States